L. Nathan Tumey joined ßÙßÇÂþ» in 2017, following 15 years of medicinal chemistry experience in the pharmaceutical and biotechnology industry. His research focuses on the design of antibody-drug-conjugates (ADCs) for the treatment of cancer, auto-immune disorders and rare diseases. Specific research projects include immune-stimulating antibody conjugates, glucocorticoid-antibody conjugates, legumain-cleavable linkers, and site-specific conjugation technology. Tumey is a leading expert in ADC technology, particularly as it applies to bioconjugation, linker design and immune-modulating payloads. He is a frequent consultant at various biotechnology and pharmaceutical companies and serves on the scientific advisory board of multiple ADC-related organizations. Tumey received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. During his years in the pharmaceutical industry, Tumey was a key leader in multiple drug-discovery programs including the development of 5HT2c agonists for obesity, PKC-theta inhibitors for asthma, IRAK4 inhibitors for rheumatoid arthritis and antibody-drug-conjugates (ADCs) for the treatment of cancer.
Nathan Tumey
Assistant Graduate Director; Vice Chair and Associate Professor, Pharmaceutical Sciences
School of Pharmacy and Pharmaceutical Sciences
Background
Education
Research Interests
Research Profile
Related News Stories